Peanut Protein Capsule Formulation for Oral Desensitization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for peanut allergy, such as dietary avoidance and self-injectable epinephrine, are burdensome and ineffective for long-term management, with only 20% of children outgrowing the allergy, and existing immunotherapy methods have limitations in consistency and stability of peanut protein delivery.
Innovation Solution
A capsule formulation containing controlled concentrations of peanut proteins Ara h1, Ara h2, and Ara h6, stabilized through RP-HPLC processing and encapsulation in HPMC capsules, which can be mixed with food for administration, ensuring consistent and stable delivery of peanut allergens for desensitization.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If peanut allergy immunotherapy is administered using natural peanut extracts, then the treatment can be simple and low-cost, but the consistency and stability of peanut protein delivery is poor
Solution Approach 1:
The patent applies parameter changes by controlling the proportion of specific peanut proteins (Ara h1, Ara h2, Ara h6) in the formulation to achieve consistent and stable delivery. By adjusting and standardizing the protein composition parameters, the therapy achieves reliable immunogenicity while maintaining a relatively simple formulation process using natural peanut extracts.
2Ease of operation
If peanut protein formulations are stored at room temperature, then ease of storage is improved, but stability of the formulation deteriorates
Solution Approach 1:
The patent addresses this contradiction by controlling the physical and chemical parameters of the formulation, including particle size distribution and protein composition. These parameter controls enhance the formulation's stability, allowing it to maintain integrity during storage while remaining easy to handle and administer.
3Reliability
If high doses of peanut protein are administered, then the desensitization effect is improved, but the risk of severe allergic reactions increases
Solution Approach 1:
The patent applies local quality by formulating with specific peanut proteins (Ara h1, Ara h2, Ara h6) in controlled proportions rather than using crude peanut extract. This targeted approach delivers the necessary immunogenicity for desensitization while potentially reducing exposure to other allergenic components, thus balancing efficacy with safety.
Solution Approach 2:
The patent uses parameter changes by precisely controlling the concentration and proportion of specific peanut proteins in the formulation. This allows optimization of the dose to achieve effective desensitization while minimizing the risk of severe reactions through standardized, controlled protein delivery.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation provides a stable and consistent delivery of peanut allergens, potentially leading to desensitization and reduced allergic reactions, with stability maintained for several months and effective at various temperatures, addressing the limitations of existing treatments.
Implementation Method 1
stabilized through RP-HPLC processing
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present application relates to a method for managing the development and manufacturing process of a therapeutically effective formulation. Peanut proteins are characterized from peanut flour and encapsulated formulations made using the peanut flour for oral immunotherapy of peanut allergies.